- IN₹1.09tn
- IN₹994.60bn
- IN₹281.63bn
India's Cipla jumps after Citi sees near-term positive triggers for earnings
Factbox: Global drugmakers invest billions to boost US presence
India raises price cap on cancer drugs to tackle shortage
Brief: Cipla Says USFDA Classified Verna Manufacturing Facility Inspection As Voluntary Action Indicated
Indian cancer patients battle shortage of key drugs as platinum costs surge
India's Cipla set for best week in nearly three years
India's Cipla rises as recovery expectations soften Q4 miss
Indian drugmaker Cipla's fourth-quarter profit misses view on weak US sales (updated)
Indian drugmaker Cipla misses Q4 profit view on weak US sales
Brief: Cipla Q4 Consol Net Profit 5.55 Billion Rupees
Preview: India's Cipla slips ahead of quarterly results on concerns over weak US sales
India's pharma stocks log best week since March 2025 on strong earnings, April sales
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
BridgeBio slips as Pfizer patent deal disappoints investors
Pfizer secures deals to keep heart drug free of generic rivals until 2031 (updated)
Brief: Pfizer reaches settlement agreements with Dexcel Pharma, Hikma & Cipla for Vyndamax
India's Cohance sees biggest pct gain in 6 years as former Cipla chief appointed CEO
India's Cipla set for best week since July 2025
Brief: Cipla Receives U.S. FDA Approval For First AB-Rated Generic Of Ventolin® Hfa